Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
Deep Track Capital, LP
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$6.1B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
63
positionsALL retained default holdings for this (filer, period), including NULL-value ones
16
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
8
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
GUARDANT HEALTH INC COMposition key pos:18541 · issuer key iss:1057 | add | +$22.4M | +538,241 | $286M | $308M | 2,800,000 | 3,338,241 | |
TARSUS PHARMACEUTICALS INC COMposition key pos:11454 · issuer key iss:2092 | add | +$6.6M | +595,966 | $246M | $253M | 3,004,034 | 3,600,000 | |
VAXCYTE INC COMposition key pos:12513 · issuer key iss:2248 | add | +$65.3M | +300,000 | $185M | $250M | 4,000,000 | 4,300,000 | |
STRUCTURE THERAPEUTICS INC SPONSORED ADSposition key sid:sec:prov:862b191ccb923fc424f39385b48ce4f8 · issuer key cusip6:86366E | add | −$79.7M | +168,066 | $286M | $206M | 4,111,782 | 4,279,848 | |
AXSOME THERAPEUTICS INC. COMposition key pos:13938 · issuer key iss:295 | trim | −$24.1M | −50,000 | $210M | $186M | 1,150,000 | 1,100,000 | |
APELLIS PHARMACEUTICALS INC COMposition key sid:sec:prov:233302be8852a126d4f3dc726082a4c4 · issuer key cusip6:03753U | trim | −$12.3M | −3,217,626 | $195M | $182M | 7,750,000 | 4,532,374 | |
OCULAR THERAPEUTIX INC COMposition key sid:sec:prov:26fd673c04b9acd4e799cbdab734d215 · issuer key cusip6:67576A | add | +$68.8M | +11,615,868 | $98.0M | $167M | 8,070,414 | 19,686,282 | |
VERA THERAPEUTICS INC CL Aposition key sid:sec:prov:c6f0567aff349dfe2dab4a6ee5ba8988 · issuer key cusip6:92337R | add | +$22.3M | +1,284,932 | $143M | $165M | 2,821,135 | 4,106,067 | |
ALUMIS INC COMposition key pos:17057 · issuer key iss:158 | new | +$149M | +6,772,595 | $0 | $149M | — | 6,772,595 | |
IONIS PHARMACEUTICALS INC COMposition key pos:12370 · issuer key iss:1221 | add | +$11.9M | +250,000 | $134M | $146M | 1,700,000 | 1,950,000 | |
NUVALENT INC COMposition key pos:14079 · issuer key iss:1594 | new | +$141M | +1,376,324 | $0 | $141M | — | 1,376,324 | |
ALKERMES PLC SHSposition key pos:16418 · issuer key iss:2418 | add | +$71.0M | +1,590,323 | $56.0M | $127M | 2,000,000 | 3,590,323 | |
CENTESSA PHARMACEUTICALS PLC SPONSORED ADSposition key pos:18882 · issuer key cusip6:152309 | add | +$75.4M | +1,158,041 | $50.0M | $125M | 2,000,000 | 3,158,041 | |
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORDposition key sid:sec:prov:66a515f74f11d5e1caa284d2543264a2 · issuer key cusip6:61559X | add | +$58.7M | +1,798,792 | $60.8M | $119M | 4,610,071 | 6,408,863 | |
MAZE THERAPEUTICS INC COMposition key pos:16236 · issuer key iss:1445 | trim | −$72.1M | −768,878 | $176M | $104M | 4,246,440 | 3,477,562 | |
ORUKA THERAPEUTICS INC COMposition key pos:14688 · issuer key iss:1638 | trim | +$34.3M | −127,307 | $65.5M | $99.8M | 2,161,510 | 2,034,203 | |
NURIX THERAPEUTICS INC COMposition key sid:sec:prov:48ac0f50c981e01f7c5af17d58a117cf · issuer key cusip6:67080M | trim | −$35.1M | −691,211 | $133M | $98.4M | 7,036,455 | 6,345,244 | |
GENMAB A/S SPONSORED ADSposition key pos:17380 · issuer key iss:1001 | new | +$98.3M | +3,663,250 | $0 | $98.3M | — | 3,663,250 | |
CYTOKINETICS INC COM NEWposition key pos:13331 · issuer key iss:700 | trim | −$121M | −1,962,678 | $212M | $90.6M | 3,336,998 | 1,374,320 | |
GRAIL INC COMposition key pos:13498 · issuer key iss:1037 | add | +$1.5M | +700,000 | $87.5M | $89.0M | 1,022,797 | 1,722,797 | |
MBX BIOSCIENCES INC COMposition key sid:sec:prov:1910147dd0682cb840152de5838d5484 · issuer key cusip6:55287L | trim | −$20.2M | −492,221 | $102M | $82.3M | 3,249,790 | 2,757,569 | |
BICARA THERAPEUTICS INC COMposition key sid:sec:prov:b23dd6a0ecec2737a5c87e9c74cf430d · issuer key cusip6:055477 | add | +$36.8M | +1,448,496 | $44.0M | $80.8M | 2,614,004 | 4,062,500 | |
COMPASS PATHWAYS PLC SPONSORED ADSposition key sid:sec:prov:88f799da4526ad1ae0a440740a6e9c1b · issuer key cusip6:20451W | add | +$16.6M | +4,827,173 | $50.6M | $67.3M | 7,334,323 | 12,161,496 | |
BIOMARIN PHARMACEUTICAL INC COMposition key pos:11882 · issuer key iss:375 | trim | −$71.7M | −1,150,000 | $137M | $65.0M | 2,300,000 | 1,150,000 | |
BRIDGEBIO PHARMA INC COMposition key pos:15468 · issuer key iss:427 | add | +$518K | +31,303 | $62.0M | $62.5M | 810,142 | 841,445 | |
IMMUNOCORE HLDGS PLC ADSposition key pos:16434 · issuer key iss:1166 | trim | −$11.3M | −72,094 | $69.6M | $58.2M | 2,003,978 | 1,931,884 | |
TANGO THERAPEUTICS INC COMposition key pos:12388 · issuer key iss:2086 | add | +$35.8M | +295,438 | $21.7M | $57.5M | 2,454,562 | 2,750,000 | |
DEFINIUM THERAPEUTICS INC COM SHSposition key pos:17580 · issuer key iss:717 | new | +$56.7M | +3,000,000 | $0 | $56.7M | — | 3,000,000 | |
TERNS PHARMACEUTICALS INC COMposition key pos:18385 · issuer key cusip6:880881 | add | +$25.5M | +304,829 | $31.1M | $56.6M | 769,048 | 1,073,877 | |
GERON CORP COMposition key sid:sec:prov:b6aaf2a1d9a7b3e3e2f1185e3325ec7d · issuer key cusip6:374163 | trim | +$4.3M | −790,993 | $42.9M | $47.3M | 32,511,271 | 31,720,278 | |
ANI PHARMACEUTICALS INC COMposition key pos:13977 · issuer key iss:27 | add | +$8.4M | +122,316 | $37.7M | $46.1M | 477,684 | 600,000 | |
CORMEDIX INC COMposition key pos:15817 · issuer key iss:661 | add | −$18.7M | +1,000,000 | $61.3M | $42.6M | 5,274,076 | 6,274,076 | |
ATAIBECKLEY INC COM SHSposition key pos:13477 · issuer key iss:265 | new | +$42.5M | +12,000,000 | $0 | $42.5M | — | 12,000,000 | |
CELLDEX THERAPEUTICS INC NEW COM NEWposition key sid:sec:prov:30f8f229420c7a82ec2ecf2f2f622045 · issuer key cusip6:15117B | trim | −$10.9M | −616,759 | $51.6M | $40.7M | 1,900,738 | 1,283,979 | |
COGENT BIOSCIENCES INC COMposition key pos:18333 · issuer key iss:610 | add | +$22.4M | +546,898 | $16.1M | $38.5M | 453,102 | 1,000,000 | |
CORVUS PHARMACEUTICALS INC COMposition key sid:sec:prov:990effbc09610fc927e1edc54d252d9d · issuer key cusip6:221015 | new | +$36.5M | +2,491,539 | $0 | $36.5M | — | 2,491,539 | |
DYNE THERAPEUTICS INC COMposition key pos:14578 · issuer key iss:778 | trim | −$15.6M | −650,000 | $51.8M | $36.3M | 2,650,000 | 2,000,000 | |
SOLENO THERAPEUTICS INC COMposition key sid:sec:prov:9c654c0b85e21e330a7ebfd2ced217c7 · issuer key cusip6:834203 | add | −$10.2M | +78,710 | $46.3M | $36.1M | 1,000,000 | 1,078,710 | |
ACLARIS THERAPEUTICS INC COMposition key sid:sec:prov:d6ea93a81ffbe77fbd59d8ff01875a57 · issuer key cusip6:00461U | new | +$35.0M | +9,345,000 | $0 | $35.0M | — | 9,345,000 | |
VERADERMICS INC COMMON STOCKposition key pos:15115 · issuer key iss:2252 | new | +$31.6M | +500,000 | $0 | $31.6M | — | 500,000 | |
VIRIDIAN THERAPEUTICS INC COMposition key sid:sec:prov:4b145c10f034612809a5ead021971789 · issuer key cusip6:92790C | trim | −$51.3M | −1,130,889 | $78.6M | $27.3M | 2,524,833 | 1,393,944 | |
X4 PHARMACEUTICALS INC COM NEWposition key sid:sec:prov:19b9675407eb505d5af586b26c66f53a · issuer key cusip6:98420X | add | +$6.1M | +1,325,874 | $20.1M | $26.2M | 5,013,661 | 6,339,535 | |
SOLID BIOSCIENCES INC COM NEWposition key pos:12592 · issuer key iss:2004 | new | +$25.7M | +3,565,062 | $0 | $25.7M | — | 3,565,062 | |
APOGEE THERAPEUTICS INC COMposition key pos:14112 · issuer key iss:217 | new | +$24.0M | +285,000 | $0 | $24.0M | — | 285,000 | |
KURA ONCOLOGY INC COMposition key sid:sec:prov:44dcd89ab4e3fa904b2bfbfadeb83d25 · issuer key cusip6:50127T | new | +$21.5M | +2,643,542 | $0 | $21.5M | — | 2,643,542 | |
CENTURY THERAPEUTICS INC COMposition key sid:sec:prov:310355a827423f86fff2dece8e909dcb · issuer key cusip6:15673T | new | +$21.4M | +9,487,745 | $0 | $21.4M | — | 9,487,745 | |
BEAM THERAPEUTICS INC COMposition key sid:sec:prov:fbdfb263adbfc86bd605b695db4205d4 · issuer key cusip6:07373V | new | +$19.6M | +820,765 | $0 | $19.6M | — | 820,765 | |
PERSONALIS INC COMposition key sid:sec:prov:67b21944302e27e04909ebe77fb217b9 · issuer key cusip6:71535D | new | +$19.1M | +3,000,000 | $0 | $19.1M | — | 3,000,000 | |
JANUX THERAPEUTICS INC COMposition key sid:sec:prov:7f79da9ff584753bfd1b9acc24c00236 · issuer key cusip6:47103J | add | +$15.3M | +1,097,701 | $1.2M | $16.5M | 89,589 | 1,187,290 | |
PROMIS NEUROSCIENCES INC COM SHSposition key sid:sec:prov:9cf954fd781de1b6ee57fd4c3c78fde3 · issuer key cusip6:74346M | new | +$10.6M | +835,655 | $0 | $10.6M | — | 835,655 | |
INVENTIVA SA ADSposition key sid:sec:prov:36f6260da0bf69546f0e601e6d5bafdc · issuer key cusip6:46124U | add | +$4.5M | +732,453 | $2.3M | $6.8M | 490,000 | 1,222,453 | |
LARIMAR THERAPEUTICS INC COMposition key sid:sec:prov:853ca021ff04669801b685877f2dabbb · issuer key cusip6:517125 | new | +$6.8M | +1,500,000 | $0 | $6.8M | — | 1,500,000 | |
CYBIN INC COM NEWposition key sid:sec:prov:f9e727b82dcd40853324f87329f6f70c · issuer key cusip6:23256X | trim | −$8.9M | −541,118 | $15.2M | $6.3M | 1,854,255 | 1,313,137 | |
| pos:13384 | exit‡e | −$16.4M | −366,435 | $16.4M | $0 | 366,435 | — | |
| pos:14561 CALL | exit‡e | −$5.6M | −500,000 | $5.6M | $0 | 500,000 | — | |
| sid:sec:prov:0983c227d7f489fadce1abda0a417532 | exit‡e | −$3.7M | −110,448 | $3.7M | $0 | 110,448 | — | |
| sid:sec:prov:3044f98940a2897deb445091c04637d0 | exit‡e | −$22.4M | −1,676,540 | $22.4M | $0 | 1,676,540 | — | |
| sid:sec:prov:6a1de202689437ba5ea3d3a29fa60708 | exit‡e | −$242M | −15,726,349 | $242M | $0 | 15,726,349 | — | |
| sid:sec:prov:7cea07f55574bfdadadb6c74621338ac | exit‡e | −$19.1M | −4,677,289 | $19.1M | $0 | 4,677,289 | — | |
| sid:sec:prov:8416c67ffd3651f6a5f8d9788c0f2e31 | exit‡e | −$6.2M | −95,408 | $6.2M | $0 | 95,408 | — | |
| sid:sec:prov:aa9011438474f45ca7c81a2864931aa4 | exit‡e | −$49.5K | −34,852 | $49.5K | $0 | 34,852 | — |
41 more changes below.
Mark-to-market only (no share change) · 10
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
SPDR SERIES TRUST STATE STREET SPDposition key pos:10981 · issuer key iss:1900 PUT | no change | +$58.0M | 0 | $1.2B | $1.3B | 10,000,000 | 10,000,000 | |
IMMUNOVANT INC COMposition key sid:sec:prov:c0680e314bfe2d1131f5c3d642c67920 · issuer key cusip6:45258J | no change | −$6.7M | 0 | $293M | $286M | 11,526,971 | 11,526,971 | |
LB PHARMACEUTICALS INC COM SHSposition key sid:sec:prov:be515631054470e2500985b7cc1d1245 · issuer key cusip6:50180M | no change | +$8.0M | 0 | $74.6M | $82.7M | 3,352,804 | 3,352,804 | |
VERASTEM INC COM NEWposition key pos:14035 · issuer key cusip6:92337C | no change | −$13.9M | 0 | $44.3M | $30.4M | 5,740,850 | 5,740,850 | |
ENGENE HOLDINGS INC COMposition key sid:sec:prov:c58e51841f60c26aab31f70d6e4eabc3 · issuer key cusip6:29286M | no change | −$9.7M | 0 | $39.5M | $29.8M | 4,377,572 | 4,377,572 | |
ENANTA PHARMACEUTICALS INC COMposition key sid:sec:prov:9f0cd92ab05ebfeeed30ea3f0847daef · issuer key cusip6:29251M | no change | −$6.1M | 0 | $30.9M | $24.7M | 1,956,867 | 1,956,867 | |
CONTEXT THERAPEUTICS INC COMposition key sid:sec:prov:1e37f227d26a900c417273e355bd6875 · issuer key cusip6:21077P | no change | +$8.5M | 0 | $10.9M | $19.4M | 7,419,355 | 7,419,355 | |
CRESCENT BIOPHARMA INC. COMposition key pos:17611 · issuer key iss:2481 | no change | +$3.0M | 0 | $5.4M | $8.3M | 453,686 | 453,686 | |
BILLIONTOONE INC CL Aposition key pos:19129 · issuer key iss:371 | no change | −$145K | 0 | $4.1M | $3.9M | 50,000 | 50,000 | |
ALIGOS THERAPEUTICS INC COM NEWposition key sid:sec:prov:c8979a8455f9af85be7efdcf54e29bb5 · issuer key cusip6:01626L | no change | −$839K | 0 | $4.1M | $3.3M | 444,110 | 444,110 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 80.3%above median 80.0%
- Concentration index
- 623 bpsabove median 446 bps
- Positions with value
- 63 / 63median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 80.3% · HHI (bps) ·§: 623integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 71
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open Deep Track Capital, LP's 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–63 of 63 positions · $6.1B disclosed value over 63 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. |
|---|---|---|---|---|---|---|---|---|
| — | — | SPDR SERIES TRUST SPDR SERIES TRUST · STATE STREET SPD · PUT CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.3B | 10,000,000 | — | 20.9% | — | |
| — | GHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GUARDANT HEALTH INC GUARDANT HEALTH INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $308M | 3,338,241 | — | 5.0% | — | |
| — | — | IMMUNOVANT INC IMMUNOVANT INC · COM CUSIP 45258J102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $286M | 11,526,971 | — | 4.7% | — | |
| — | TARSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TARSUS PHARMACEUTICALS INC TARSUS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $253M | 3,600,000 | — | 4.1% | — | |
| — | PCVXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VAXCYTE INC VAXCYTE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $250M | 4,300,000 | — | 4.1% | — | |
| — | — | STRUCTURE THERAPEUTICS INC STRUCTURE THERAPEUTICS INC · SPONSORED ADS CUSIP 86366E106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $206M | 4,279,848 | — | 3.4% | — | |
| — | AXSMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | AXSOME THERAPEUTICS INC. AXSOME THERAPEUTICS INC. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $186M | 1,100,000 | — | 3.0% | — | |
| — | — | APELLIS PHARMACEUTICALS INC APELLIS PHARMACEUTICALS INC · COM CUSIP 03753U106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $182M | 4,532,374 | — | 3.0% | — | |
| — | — | OCULAR THERAPEUTIX INC OCULAR THERAPEUTIX INC · COM CUSIP 67576A100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $167M | 19,686,282 | — | 2.7% | — | |
| — | — | VERA THERAPEUTICS INC VERA THERAPEUTICS INC · CL A CUSIP 92337R101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $165M | 4,106,067 | — | 2.7% | — | |
| — | ALMSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ALUMIS INC ALUMIS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $149M | 6,772,595 | — | 2.4% | — | |
| — | IONSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IONIS PHARMACEUTICALS INC IONIS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $146M | 1,950,000 | — | 2.4% | — | |
| — | NUVLverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NUVALENT INC NUVALENT INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $141M | 1,376,324 | — | 2.3% | — | |
| — | ALKSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ALKERMES PLC ALKERMES PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $127M | 3,590,323 | — | 2.1% | — | |
| — | — | CENTESSA PHARMACEUTICALS PLC CENTESSA PHARMACEUTICALS PLC · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $125M | 3,158,041 | — | 2.0% | — | |
| — | — | MOONLAKE IMMUNOTHERAPEUTICS MOONLAKE IMMUNOTHERAPEUTICS · CLASS A ORD CUSIP 61559X104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $119M | 6,408,863 | — | 2.0% | — | |
| — | — | MAZE THERAPEUTICS INC MAZE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $104M | 3,477,562 | — | 1.7% | — | |
| — | ORKAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ORUKA THERAPEUTICS INC ORUKA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $99.8M | 2,034,203 | — | 1.6% | — | |
| — | — | NURIX THERAPEUTICS INC NURIX THERAPEUTICS INC · COM CUSIP 67080M103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $98.4M | 6,345,244 | — | 1.6% | — | |
| — | GMABverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GENMAB A/S GENMAB A/S · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $98.3M | 3,663,250 | — | 1.6% | — | |
| — | CYTKverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CYTOKINETICS INC CYTOKINETICS INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $90.6M | 1,374,320 | — | 1.5% | — | |
| — | GRALverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GRAIL INC GRAIL INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $89.0M | 1,722,797 | — | 1.5% | — | |
| — | — | LB PHARMACEUTICALS INC LB PHARMACEUTICALS INC · COM SHS CUSIP 50180M108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $82.7M | 3,352,804 | — | 1.4% | — | |
| — | — | MBX BIOSCIENCES INC MBX BIOSCIENCES INC · COM CUSIP 55287L101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $82.3M | 2,757,569 | — | 1.3% | — | |
| — | — | BICARA THERAPEUTICS INC BICARA THERAPEUTICS INC · COM CUSIP 055477103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $80.8M | 4,062,500 | — | 1.3% | — | |
| — | — | COMPASS PATHWAYS PLC COMPASS PATHWAYS PLC · SPONSORED ADS CUSIP 20451W101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $67.3M | 12,161,496 | — | 1.1% | — | |
| — | BMRNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIOMARIN PHARMACEUTICAL INC BIOMARIN PHARMACEUTICAL INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $65.0M | 1,150,000 | — | 1.1% | — | |
| — | BBIOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BRIDGEBIO PHARMA INC BRIDGEBIO PHARMA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $62.5M | 841,445 | — | 1.0% | — | |
| — | IMCRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IMMUNOCORE HLDGS PLC IMMUNOCORE HLDGS PLC · ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $58.2M | 1,931,884 | — | 1.0% | — | |
| — | TNGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TANGO THERAPEUTICS INC TANGO THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $57.5M | 2,750,000 | — | 0.9% | — | |
| — | DFTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DEFINIUM THERAPEUTICS INC DEFINIUM THERAPEUTICS INC · COM SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $56.7M | 3,000,000 | — | 0.9% | — | |
| — | — | TERNS PHARMACEUTICALS INC TERNS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $56.6M | 1,073,877 | — | 0.9% | — | |
| — | — | GERON CORP GERON CORP · COM CUSIP 374163103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $47.3M | 31,720,278 | — | 0.8% | — | |
| — | ANIPverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ANI PHARMACEUTICALS INC ANI PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $46.1M | 600,000 | — | 0.8% | — | |
| — | CRMDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CORMEDIX INC CORMEDIX INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $42.6M | 6,274,076 | — | 0.7% | — | |
| — | ATAIverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ATAIBECKLEY INC ATAIBECKLEY INC · COM SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $42.5M | 12,000,000 | — | 0.7% | — | |
| — | — | CELLDEX THERAPEUTICS INC NEW CELLDEX THERAPEUTICS INC NEW · COM NEW CUSIP 15117B202 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $40.7M | 1,283,979 | — | 0.7% | — | |
| — | COGTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | COGENT BIOSCIENCES INC COGENT BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $38.5M | 1,000,000 | — | 0.6% | — | |
| — | — | CORVUS PHARMACEUTICALS INC CORVUS PHARMACEUTICALS INC · COM CUSIP 221015100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $36.5M | 2,491,539 | — | 0.6% | — | |
| — | DYNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DYNE THERAPEUTICS INC DYNE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $36.3M | 2,000,000 | — | 0.6% | — | |
| — | — | SOLENO THERAPEUTICS INC SOLENO THERAPEUTICS INC · COM CUSIP 834203309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $36.1M | 1,078,710 | — | 0.6% | — | |
| — | — | ACLARIS THERAPEUTICS INC ACLARIS THERAPEUTICS INC · COM CUSIP 00461U105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $35.0M | 9,345,000 | — | 0.6% | — | |
| — | MANEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VERADERMICS INC VERADERMICS INC · COMMON STOCK CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $31.6M | 500,000 | — | 0.5% | — | |
| — | — | VERASTEM INC VERASTEM INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $30.4M | 5,740,850 | — | 0.5% | — | |
| — | — | ENGENE HOLDINGS INC ENGENE HOLDINGS INC · COM CUSIP 29286M105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $29.8M | 4,377,572 | — | 0.5% | — | |
| — | — | VIRIDIAN THERAPEUTICS INC VIRIDIAN THERAPEUTICS INC · COM CUSIP 92790C104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $27.3M | 1,393,944 | — | 0.4% | — | |
| — | — | X4 PHARMACEUTICALS INC X4 PHARMACEUTICALS INC · COM NEW CUSIP 98420X202 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $26.2M | 6,339,535 | — | 0.4% | — | |
| — | SLDBverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SOLID BIOSCIENCES INC SOLID BIOSCIENCES INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $25.7M | 3,565,062 | — | 0.4% | — | |
| — | — | ENANTA PHARMACEUTICALS INC ENANTA PHARMACEUTICALS INC · COM CUSIP 29251M106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $24.7M | 1,956,867 | — | 0.4% | — | |
| — | APGEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | APOGEE THERAPEUTICS INC APOGEE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $24.0M | 285,000 | — | 0.4% | — | |
| — | — | KURA ONCOLOGY INC KURA ONCOLOGY INC · COM CUSIP 50127T109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $21.5M | 2,643,542 | — | 0.4% | — | |
| — | — | CENTURY THERAPEUTICS INC CENTURY THERAPEUTICS INC · COM CUSIP 15673T100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $21.4M | 9,487,745 | — | 0.4% | — | |
| — | — | BEAM THERAPEUTICS INC BEAM THERAPEUTICS INC · COM CUSIP 07373V105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.6M | 820,765 | — | 0.3% | — | |
| — | — | CONTEXT THERAPEUTICS INC CONTEXT THERAPEUTICS INC · COM CUSIP 21077P108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.4M | 7,419,355 | — | 0.3% | — | |
| — | — | PERSONALIS INC PERSONALIS INC · COM CUSIP 71535D106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.1M | 3,000,000 | — | 0.3% | — | |
| — | — | JANUX THERAPEUTICS INC JANUX THERAPEUTICS INC · COM CUSIP 47103J105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $16.5M | 1,187,290 | — | 0.3% | — | |
| — | — | PROMIS NEUROSCIENCES INC PROMIS NEUROSCIENCES INC · COM SHS CUSIP 74346M505 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.6M | 835,655 | — | 0.2% | — | |
| — | CBIOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CRESCENT BIOPHARMA INC. CRESCENT BIOPHARMA INC. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.3M | 453,686 | — | 0.1% | — | |
| — | — | INVENTIVA SA INVENTIVA SA · ADS CUSIP 46124U107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.8M | 1,222,453 | — | 0.1% | — | |
| — | — | LARIMAR THERAPEUTICS INC LARIMAR THERAPEUTICS INC · COM CUSIP 517125100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.8M | 1,500,000 | — | 0.1% | — | |
| — | — | CYBIN INC CYBIN INC · COM NEW CUSIP 23256X407 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.3M | 1,313,137 | — | 0.1% | — | |
| — | BLLNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BILLIONTOONE INC BILLIONTOONE INC · CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.9M | 50,000 | — | 0.1% | — | |
| — | — | ALIGOS THERAPEUTICS INC ALIGOS THERAPEUTICS INC · COM NEW CUSIP 01626L204 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.3M | 444,110 | — | 0.1% | — |
1–63 of 63 positions · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).